Prelude Therapeutics rises after FDA clears early-stage trial of blood cancer drug

Prelude Therapeutics Incorporated

03/02/2026 14:29

** Shares of  drug developer Prelude Therapeutics PRLD.O rise 6.85% to $2.13 premarket

**  Company says U.S. FDA has cleared human testing of its experimental drug, PRT12396, for polycythemia vera and myelofibrosis — blood cancers where the body makes too many abnormal blood cells

** PRLD says the early-stage study will assess safety and initial signs of benefit in patients with high-risk disease

** PRT12396 is designed to target a genetic mutation common in both conditions - PRLD

** Company expects to begin enrolling patients by Q2 2026 and says it has an exclusive option deal on the program with Incyte INCY.O

** Shares more than doubled in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))